European regulators have postponed a decision on whether to recommend approval of a closely watched Bristol-Myers Squibb drug that helps the immune system fight cancer, officials said on Friday.

Nivolumab, which is already approved in the United States under the brand name Opdivo for melanoma and lung cancer, was on the agenda at a monthly meeting of European Medicines Agency (EMA) experts, but no verdict was reached. 

The committee is considering whether to recommend the antibody medicine for treating advanced melanoma in adults.

A Bristol-Myers spokeswoman said the delay was due to the fact that the drugmaker had submitted additional data over the course of the review period. She declined to give details.

For more details, go to: http://www.reuters.com/article/2015/03/27/bristol-myers-europe-idUSL6N0WT3BE20150327